Supplementary materials: Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA

These are peer-reviewed supplementary materials for the article 'Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1: Treatment duration of DMT used prior to switching to alemtuzumab (pre-index period). Supplementary Table 2: Average healthcare costs per person at index date (initiation of alemtuzumab).Supplementary Figure 1: Study design.Aim: Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies (DMTs). Patients & methods: Retrospective, observational study of IBM MarketScan claims database. PwMS previously treated with DMTs and initiating alemtuzumab (1 January 2013 to 31 December 2019) were identified. “Index” was date of alemtuzumab initiation (prescription filled). Results: The study cohort (n = 341) was primarily female (72%) with mean ± standard deviation) age 45.1 ± 9.5 years. At index, duration of MS was 5.3 ± 2.8 years. HCRU (inpatient/outpatient services), outpatient costs (including MS-specific MRI and emergency room visits) and annualized relapse rate significantly reduced over the 2 years following initiation of alemtuzumab. DMT costs reduced over the same period. Conclusion: Health economic and clinical benefits were seen following switching to alemtuzumab from other DMTs for treatment of MS, in this cohort from the USA.

此为发表于《比较疗效研究杂志》的论文《美国多发性硬化症患者由其他疾病修饰疗法切换至阿仑珠单抗的经济效益》的同行评审补充材料。补充表1：切换至阿仑珠单抗前使用DMT的治疗持续时间。补充表2：基准日期（阿仑珠单抗起始）的每人平均医疗保健成本。补充图1：研究设计。目的：描述多发性硬化症患者（pwMS）由其他疾病修饰疗法（DMTs）切换至阿仑珠单抗时的人口统计学特征、临床特征、医疗保健资源利用（HCRU）及成本。患者与方法：对IBM MarketScan索赔数据库进行的回顾性、观察性研究。识别出先前接受DMT治疗并开始使用阿仑珠单抗的患者（2013年1月1日至2019年12月31日）。“基准”日期定义为阿仑珠单抗的起始日期（处方填写）。结果：研究队列（n=341）以女性为主（72%），平均年龄±标准差为45.1±9.5岁。在基准日期时，MS的病程为5.3±2.8年。在阿仑珠单抗起始后的两年中，医疗保健资源利用（住院/门诊服务）、门诊成本（包括MS特异性MRI和急诊室访问）以及年度化复发率显著降低。DMT成本在同一时期内也有所下降。结论：在美国的这一队列中，从其他DMTs切换至阿仑珠单抗治疗MS后，观察到健康经济效益和临床效益。